LSE%3AFARN

Faron Pharma reports improved remission rates from Bexmab Phase 1 trial to treat patients with aggressive cancers

Faron Pharmaceuticals (LSE: FARN) has reported positive data from Phase 1 of an ongoing trial investigating bexmarilimab (Bexmab) in combination with standard of care in aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Four out of five initial Phase 1 patients have now been on Bexmab with azacitidine for more than […]